MLA-NHS

Fig. 3

PDP-morpholino antisense oligonucleotide




Fig. (

PMLA-NHS ester


$$x = 4.6\%$$


 $y = 19.3\%$
 $z = 47\%$
 $w = 29.1\%$

Fig. 7

PMLA/L-valine/2-mercaptoethylamine/mPEG₅₀₀₀-NH₂ conjugate

Fig. 8










Fig. 10b



%







Fig. 13



, p<0.001 no treatment vs. normal brain; *, p<0.001 no treatment vs. treatment





FIg. 14

laminin $\beta 1$



untreated tumor

Drug 2-treated tumor

Fig. 15

Fig. 16




Fig. 17

